AMR Action Fund
Carly joined the AMR Action Fund as an analyst in November 2021. She received her MS in cell biology and PhD in microbiology at Rutgers University. During her doctoral and post-doctoral research, she developed and evaluated a novel anti-tubercular drug candidate. Additionally, she used a multi-omics approach to characterize the physiology of drug-tolerant Mycobacterium tuberculosis isolates. Carly's scientific work has led to several publications and recognition through various awards.
This person is not in any offices
AMR Action Fund
The AMR Action Fund is a ground-breaking collective venture launched by more than 20 leading pharmaceutical companies to bring 2 to 4 new antibiotics to patients by the end of the decade.